t-butyl 4-(thiophen-3-ylamino)piperidine-1-carboxylate | 1012044-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: t-butyl 4-(thiophen-3-ylamino)piperidine-1-carboxylate
• 英文别名: 1,1-dimethylethyl 4-(3-thienylamino)-1-piperidinecarboxylate；t-Butyl 4-(thiophen-3-ylamino)piperidine-1-carboxylate；tert-butyl 4-(thiophen-3-ylamino)piperidine-1-carboxylate
• CAS: 1012044-06-2
• 化学式: C₁₄H₂₂N₂O₂S
• 分子量: 282.407
• InChiKey: FOSNLXHSIYJVHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  69.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-溴噻吩 、 1-Boc-4-氨基哌啶 在 2-双环己基膦-2',6'-二甲氧基联苯 、 tris-(dibenzylideneacetone)dipalladium(0) sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以16%的产率得到t-butyl 4-(thiophen-3-ylamino)piperidine-1-carboxylate
  参考文献：
  名称：

  EP2060563

  摘要：

  公开号：

文献信息

• [EN] CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS<br/>[FR] ANTAGONISTES DE CCR5 EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009058919A1

  公开（公告）日：2009-05-07

  The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及在治疗CCR5相关疾病和疾病中有用的化合物，例如，在抑制HIV复制、预防或治疗HIV感染以及治疗由此导致的获得性免疫缺陷综合症（AIDS）方面有用。
• CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE
  申请人：Ozawa Michinori

  公开号：US20100179118A1

  公开（公告）日：2010-07-15

  The present invention relates to a compound represented by the following formula (I), which is useful as an antiallergic agent and/or an anti-inflammatory agent, or a physiologically acceptable salt thereof and the like: wherein R 1 and R 2 are the same or different and each is an optionally substituted aryl group and the like, R 3 is a hydrogen atom, a C 1-6 alkyl group and the like, R 4 and R 5 are the same or different and each is a hydrogen atom, a halogen atom, a hydroxy group, a C 1-6 alkyl group and the like, X is a single bond or —C(R 6 )(R 7 )—, R 6 and R 7 are the same or different and each is a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group and the like, or R 6 and R 7 optionally form, together with the carbon atom bonded thereto, an optionally substituted C 3-8 cycloalkyl group and the like, ring group A is an azetidin-1-yl group and the like, m is 0, 1 or 2, and n is 0, 1 or 2.

  本发明涉及以下式（I）所表示的化合物或其生理上可接受的盐等，其可用作抗过敏剂和/或抗炎剂： 其中，R1和R2相同或不同，每个都是可选取的取代芳基基团等；R3是氢原子、C1-6烷基基团等；R4和R5相同或不同，每个都是氢原子、卤原子、羟基、C1-6烷基基团等；X是单键或—C(R6)(R7)—；R6和R7相同或不同，每个都是氢原子、卤原子、可选取的取代C1-6烷基基团等，或R6和R7可选择性地与与其相连的碳原子一起形成可选取的取代C3-8环烷基团等；环基团A是氮杂环丙烷基团等；m为0、1或2；n为0、1或2。